Core Viewpoint - The company, Yuyantang, has submitted its prospectus to the Hong Kong Stock Exchange, with Zhuhai International and Guoyuan International acting as joint sponsors, focusing on a "full lifecycle diagnosis and treatment model" based on Traditional Chinese Medicine (TCM) principles [1] Group 1: Business Model - The company operates on a "preventive treatment" philosophy, covering four stages: "pre-disease, desire for disease, existing disease, and post-recovery," providing integrated personalized health solutions that include prevention, adjustment, treatment, and maintenance [1] - Yuyantang employs a strict model of "offline initial diagnosis and online follow-up," ensuring all patients complete diagnostic assessments at licensed offline institutions, while the online platform manages follow-ups, chronic disease care, and health management to ensure service continuity [1] Group 2: Market Position - According to a Frost & Sullivan report, Yuyantang ranks as the second-largest private chain TCM healthcare service provider in Northern China by total revenue from TCM outpatient services and clinics as of 2024, and it ranks first in revenue from medicinal pastes [1] - The company boasts the highest customer repurchase rate among private chain TCM healthcare service providers, achieving a repurchase rate of 81.1% for the nine months ending September 30, 2025 [1] Group 3: Infrastructure and Expertise - Yuyantang has established a network of 48 self-built and operated licensed medical institutions in Northern China, all managed through a unified cloud-based healthcare information system (HIS) for digital management [1] - The company offers personalized TCM prescriptions, including decoctions, pills, powders, and pastes, and possesses proprietary non-heritage pastes and several in-house developed formulations as protected therapeutic assets [1] - Yuyantang employs 292 full-time medical professionals, with a research committee comprising 98 experts, integrating knowledge from both internal medical teams and external research collaborators [1]

Core Viewpoint - Harbin Yuyuantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance its market position in the traditional Chinese medicine sector [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyuantang's full lifecycle diagnosis and treatment model covers disease prevention, adjustment, treatment, and health maintenance, providing personalized and continuous health management services [2][7]. - The company has established a network of 48 self-operated licensed medical institutions in Northern China, utilizing a unified cloud-based medical information system for digital management [2][6]. Group 2: Market Position and Customer Loyalty - According to a report by Frost & Sullivan, Yuyuantang ranks second among private chain TCM medical service providers in Northern China by total revenue and first in revenue from medicinal pastes [1]. - The company's customer repurchase rate reached 81.1% as of September 30, 2025, indicating strong market recognition of its service value and efficacy [3]. Group 3: Product Development and Supply Chain - Yuyuantang adheres to the "one person, one prescription" principle, offering various personalized traditional Chinese medicine formulations, including decoctions, pills, powders, and pastes [4]. - The company has developed proprietary non-heritage pastes that enhance patient compliance and serve as key components in chronic disease management [4]. - Yuyuantang is focused on building a dedicated facility for producing traditional Chinese medicine pieces, ensuring supply chain security and quality control through vertical integration [6]. Group 4: Strategic Outlook - The company plans to expand its geographic footprint in provinces such as Shandong, Hebei, Henan, and Tianjin, while enhancing resource allocation and market influence [6]. - With the ongoing implementation of the "Healthy China 2030" initiative and various TCM revitalization policies, the market for TCM medical services is poised for systematic growth, aligning with the increasing demand for long-term health management [7].

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance patient care and capitalize on the growing demand for traditional Chinese medicine services in China [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyantang's "full lifecycle diagnosis and treatment model" covers the stages of "preventive care, disease management, treatment, and recovery," providing personalized health management solutions through modern TCM assessment tools and big data analysis [2][3]. - The company has established a network of 48 self-operated licensed medical institutions in northern China, utilizing a unified cloud-based medical information system for digital management [3]. Group 2: Product Offerings - Yuyantang adheres to the "one person, one prescription" principle, offering various personalized TCM formulations, including decoctions, pills, powders, and ointments, which enhance patient compliance and serve as key components in chronic disease management [4]. - The company has proprietary non-heritage ointments and several self-developed hospital formulations that are continuously refined based on clinical experience, forming a standardized and clinically validated foundation for its services [4]. Group 3: Talent and Team Structure - The company employs 292 full-time medical professionals, ensuring stable and continuous service quality, while its research committee consists of 98 experts, driving innovation and maintaining high standards in patient care [5]. Group 4: Supply Chain and Production Strategy - Yuyantang's core strategy includes building a dedicated facility for producing TCM raw materials, which enhances supply chain security and quality control from raw materials to final products [6]. - The company aims to expand its regional presence in provinces such as Shandong, Hebei, Henan, and Tianjin, while digitally transforming its production facilities to ensure quality assurance [6]. Group 5: Market Opportunities - The traditional Chinese medicine service market is experiencing systemic growth opportunities due to the "Healthy China 2030" initiative and various TCM revitalization policies, aligning with the increasing demand for long-term health management [7]. - Yuyantang's innovative service model and integrated operational ecosystem position it well for accelerated growth through its upcoming public listing, reflecting a shift in the private TCM sector towards standardized and sustainable high-quality development [7].

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. (Yuyantang) is set to list on the Hong Kong Stock Exchange, aiming to expand its traditional Chinese medicine services through a fully integrated treatment model and a self-built network of licensed medical institutions [3][5]. Group 1: Company Overview - Yuyantang was established in 2018 and operates a network of 48 self-built licensed medical institutions in Northern China, ensuring standardized operations and consistent care quality [5]. - The company ranks fifth among private chain TCM service providers in China by total revenue and first in revenue from traditional Chinese medicine preparations [5]. - Yuyantang has a high customer loyalty rate, with a repurchase rate of 81.1% in the first three quarters of 2025 [5]. Group 2: Service Model and Offerings - The company follows a "one person, one prescription" principle, offering personalized TCM preparations, including decoctions, pills, powders, and ointments, enhancing patient compliance [6]. - Yuyantang has developed proprietary in-house formulations based on clinical experience, which are integral to its chronic disease management processes [6]. Group 3: Workforce and Innovation - As of January 6, 2026, Yuyantang employs 292 full-time medical professionals and has a research committee of 98 experts, driving innovation and improving patient care standards [7]. - The TCM service market in China is projected to grow from 659.9 billion yuan in 2019 to 1,020.16 billion yuan by 2024, with a compound annual growth rate of 10.1% expected until 2029 [7]. Group 4: Future Development Plans - Yuyantang plans to expand its geographic footprint in provinces like Shandong, Hebei, Henan, and Tianjin, focusing on self-built and self-operated models to enhance market penetration [8]. - The company aims to digitally transform its production facilities and strengthen its service and product value through standardized TCM services and backend product collaboration [8]. Group 5: Financial Performance - Yuyantang's revenue for 2023 and 2024 is projected at 150 million yuan and 215 million yuan, respectively, reflecting a year-on-year growth of 43.5% [8]. - For the first three quarters of 2025, revenue increased by 96.6% to 284 million yuan compared to the same period in 2024 [8]. - The adjusted net profit margins for 2023, 2024, and the first three quarters of 2025 are 13.7%, 12.6%, and 21.7%, respectively [9]. Group 6: IPO Fund Utilization - Approximately 33% of the IPO proceeds will be used to open new licensed medical institutions, while 24% will enhance production capacity [9]. - Other allocations include 10% for developing intelligent systems, 10% for brand enhancement, and 5% for optimizing TCM services, particularly in in-house formulations [9].